Clinical Trial Update: Neoadjuvant Darovasertib in Primary Uveal Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 neoadjuvant trial of darovasertib for primary uveal melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Darovasertib (darovasertib)

Snippet

Sponsor: IDEAYA Biosciences | Conditions: Uveal Melanoma | Phase 3 | Status: RECRUITING